BOSTON, April 5, 2011 (GLOBE NEWSWIRE) -- Oncology Care Live ( www.OncologyCarelive.com ), the live online oncology congress, today announced that Michael J. Borowitz, M.D., Ph.D., and Robert A. Brodsky, M.D., both of Johns Hopkins University School of Medicine, will be presenting live online via video on Wednesday April 27th on the diagnosis and treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). Attendees will be able to garner real-time answer to their questions to presenting faculty. Paroxysmal Nocturnal Hemoglobinuria, also sometimes referred to as Marchiafava-Micheli syndrome, is rare, occurring in only 1-2 persons per million. PNH may go undiagnosed because some symptoms of PNH may also be symptoms of other bone marrow diseases and because the disease may not at first be suspected given its rarity. Early diagnosis is vital, given the life-threatening and progressive nature of the disease. PNH is characterized by complement-induced intravascular hemolytic anemia (anemia due to destruction of red blood cells in the bloodstream), red urine (due to the appearance of hemoglobin in the urine) and thrombosis.
Dr. Michael J. Borowitz will be presenting live via video online on the "Detection and Diagnosis of Paroxysmal Nocturnal Hemoglobinuria (PNH)" on Wednesday April 27th at 12:00 PM Eastern. Dr. Borowitz is an internationally renowned hematopathologist with particular expertise in the flow cytometric diagnosis of hematologic malignancies. He has been a leader in numerous organizations concerned with the clinical application of this technology and is co-author of the "Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry" for the Clinical Cytometry Society.
Dr. Robert A. Brodsky will be presenting live via video online on "Best Practices in Treatments of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)" at 1:00 PM Eastern on April 27th. Dr. Brodsky's major clinical research involves the study of aplastic anemia, PNH and other bone marrow failure disorders. His research shows that immunoablative doses of cyclophosphamide, without bone marrow transplantation, can lead to durable complete remissions in severe aplastic anemia.
This meeting at Oncology Care Live is being sponsored by Alexion Pharmaceuticals. Alexion is a global biopharmaceutical company that combines science with a commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Oncology Care Live is tuition-free for healthcare professionals who need to stay abreast of the latest advances in this fast-moving field. To register now for free, visit www.OncologyCareLive.com.
ABOUT ONCOLOGY CARE LIVE
Oncology Care Live ( www.OncologyCareLive.com ) is a virtual medical congress that enables healthcare practitioners and others interested in understanding and utilizing the latest cancer care treatments to learn, connect and interact in real time. Oncology Care Live offers education online at no cost and delivers all the benefits of a physical conference, with live keynote presentations, lectures, peer networking and an exhibit floor, from the convenience of a computer.
ABOUT ALEXION PHARMACEUTICALS
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company working to develop and deliver life-changing drug therapies for patients with serious and life-threatening medical conditions. Alexion is engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with a wide array of severe disease states, including hematologic and kidney diseases, transplant, other inflammatory disorders, and cancer. Further information about Alexion Pharmaceuticals, Inc. can be found at: www.alexionpharma.com.
Oncology Care Live and PlatformQ are trademarks of PlatformQ, LLC. All other trademarks or service marks are property of their respective owners.
This information was brought to you by Cision
The following pictures are available for download: